Impact of fibronectin type III domain-containing family in the changes in metabolic and hormonal profiles during peripartum period in dairy cows

Mathilde Daudon¹,², Christelle Ramé¹, Anthony Estienne³, Christopher Price²*,† and Joëlle Dupont²*,†

¹CNRS, IFCE, INRAE, Université de Tours, PRC, Breeding system and Animal Physiology Department, Nouzilly, France, ²Centre de Recherche en Reproduction et Fertilité, Faculté de Médecine Vétérinaire, Université de Montréal, St-Hyacinthe, QC, Canada

The peripartum period in dairy cows is frequently associated with excessive lipolysis due to Negative Energy Balance (NEB). These metabolic disorders are the cause of various pathologies. Some metabolites such as β-hydroxybutyrate (BHBA) and Non-Esterified Fatty Acids (NEFA) are known to be biomarkers of NEB in dairy cows. The involvement of adipokines, including adiponectin and leptin, during fat mobilization in the peripartum period is well described, but little is known about the impact of myokines at this time. Fibronectin type III domain-containing proteins (FNDC) are myokines and adipokines recently discovered to play a role in metabolic dysfunctions. This study aimed to evaluate some FNDCs (FNDC5, 4, 3A and B) as potential plasma and adipose tissue indicators of NEB in cattle. We measured plasma FNDC concentrations and adipose tissue FNDC gene expression during the peripartum period. We showed that recombinant human irisin (a fragmented product of FNDC5) increased the release of glycerol and abundance of mRNA encoding adipose triglyceride lipase and hormone-sensitive-lipase in bovine and human adipose tissue explants. In conclusion, FNDC5 is expressed in bovine adipose tissue and may be involved in lipid mobilization and regulation of NEB in cattle.

KEYWORDS
fibronectin type III domain-containing proteins, irisin, negative energy balance, dairy cows, adipokine, myokine
Introduction

At the beginning of lactation, a massive change in energy balance occurs in dairy cows resulting in mobilization of adipose and muscle tissues (1). The period between 3 weeks before and 3 weeks after parturition is defined as the "transition period" (2) and it is a key period for the next breeding season (1). Many metabolic adaptations occur with the onset of lactation when the energy requirements for milk production exceed energy consumption and the animal enters a state of negative energy balance (NEB). Although NEB is a physiological adaptation, it has a deleterious impact on the postpartum recovery of ovarian activity and fertility (1) and lactation performance (3) if the animal cannot cope with the severity and magnitude of NEB. The average duration of postpartum NEB is ~45 days [with a standard deviation of 21 days; (4)]. NEB leads to a mobilization of adipose tissue and the release of non-esterified fatty acids (NEFA) into the blood (5), which are the first two physiological adaptations to appear in order to meet the energy requirements of lactation. The liver removes circulating NEFA in the blood by metabolizing them into ketone bodies (6). An excess of ketone bodies in the blood leads to ketosis that can affect milk production (7) and fertility (5), with reproductive disorders affecting both the morphology of the cumulus oocyte complex and the viability of the embryo (8), increased uterine/placental incompetence (9) and an increased incidence of metritis and mastitis (10). The major circulating ketone body in cows is β-hydroxybutyrate (BHBA) and increased blood concentrations of BHBA is a marker of ketosis (11). During the periparturient period, lipogenesis is decreased and lipolysis is increased in adipose tissue by various physiological processes. For example, plasma insulin and glucose concentrations are decreased and concentrations of catecholamines, growth hormone, and glucocorticoids are increased (12). Furthermore, the profiles of many adipokines such as leptin, adiponectin (13–16), resistin (17, 18) and other biomarkers of lipid metabolism and inflammation (19) have been investigated in serum and/or adipose tissue of dairy cows during the periparturient period. Indeed, it has been shown that plasma leptin decreased before parturition and during period of undernutrition (20) and in opposite plasma resistin increased after parturition (13). Plasma adiponectin decreased before calving and increased after parturition (13). Moreover, glycerol release and adipose triglyceride lipase (ATGL) and hormone sensitive lipase (HSL) are involved in basal lipolysis (21). However, the transition period is also associated with the mobilization of muscle tissue (22–24), although this is secondary to fat mobilization (25, 26). Muscles secrete myokines, but whether myokine concentrations change during the peripartum period is unknown.

Recently, a new group of adipokines/myokines has been described, the fibronectin type III domain containing (FNDC), A family of membrane protein. Their various functions include tissue development and cell adhesion, migration and proliferation (27). This family contains FNDC3A, FNDC3B, FNDC4 and FNDC5 among others (28–31). FNDC5 is the most studied because it is the precursor of irisin, discovered in 2012 as a myokine involved in the regulation of thermogenesis in white adipose tissue in response to cold and exercise in mice and humans (32) by upregulating the Peroxisome Proliferator Activated Receptor γ (PPARγ) and Uncoupling Protein 1 (UCP1) (31, 33). Thus, irisin could be considered as a browning inducing endocrine hormone (32, 34, 35), presumably acting via integrin subunit beta 1 (ITGB1) and integrin subunit alpha V (ITGAV) as receptors (36) and the mitogen-activated protein kinase 3/1 (MAPK3/1) signaling pathway. It has also been suggested that full-length transmembrane FNDC5 could act as a receptor in the HEK-293 cell line (37). FNDC3B, also known as Factor for Adipocyte Differentiation 104 (Fad104), stimulates adipogenesis in mice (38) and its paralogue FNDC3A is expressed in Leydig cells and spermatids and is necessary for sperm maturation in mice (39). Similarly to FNDC5, FNDC4 is cleaved and releases a functional active peptide in the bloodstream that has recently been identified as an adipokine in humans (40). Abundance of FNDC4 mRNA is elevated in adipose tissue of obese patients, and exogenous FNDC4 inhibited lipogenesis in human visceral adipocytes in vitro through the adhesion G-protein-coupled receptor F5 [ADGRF5, also known as G-protein-coupled receptor 116 (GPR116)] (40, 41) and upregulates UCP1 as well as FNDC5 (40).

As the four FNDCs described above are adipokines/myokines, we hypothesize that these FNDCs are linked to the NEB and the fat mobilization occurring during the transition period in the dairy cow. The objectives of the present study were to determine the tissue distribution of FNDC gene expression in cattle, and to determine adipose mRNA abundance and plasma concentrations of these FNDCs during the periparturient period and their correlations with zootechnical parameters, plasma metabolites and hormone profiles. Finally, we investigated the involvement of FNDC5/irisin in lipolysis of bovine adipose tissue by using explant cultures.
Table 1. Zootechnical parameters and plasma metabolites and hormonal concentrations in the high negative energy balance (HNEB, n = 13) and low negative energy balance (LNEB, n = 8) dairy cow groups at 4 WAP, 1 WPP and 16 WPP.

| Parameter                    | HNEB          | LNEB          |
|------------------------------|---------------|---------------|
|                              | 4 WAP Mean ± SEM | 1 WPP Mean ± SEM | 16 WPP Mean ± SEM | 4 WAP Mean ± SEM | 1 WPP Mean ± SEM | 16 WPP Mean ± SEM |
| Energy balance (Mcal/day)     | ND            | −12.16 ± 0.53 | −8.33 ± 1.84     | ND              | −5.60 ± 0.77     | 0.11 ± 1.43      | <0.0001 | 0.0010 | 0.5832 |
| Dry matter intake (kg/day)   | NS            | 12.20 ± 1.4   | 15.51 ± 1.24     | ND              | 13.09 ± 1.75     | 22.10 ± 1.69     | 0.0049 | 0.0002 | 0.0849 |
| Live body weight (kg/day)    | 658.85 ± 18.4 | 564.35 ± 17.74 | 525.75 ± 14.63  | 687.44 ± 18.91 | 602.76 ± 19.94  | 569.27 ± 15.83  | 0.0151 | <0.0001 | 0.9155 |
| Variation of empty body weight (kg/day) | 0   | −14.39 ± 1.07 | −20.13 ± 1.02   | ND              | −12.49 ± 1.84    | −17.40 ± 2.15    | 0.1202 | <0.0001 | 0.5099 |
| Milk yield (kg/day)          | ND            | 24.20 ± 1.82  | 30.25 ± 1.59     | ND              | 21.60 ± 2.13     | 33.57 ± 2.30     | 0.8585 | <0.0001 | 0.1383 |
| Fat energy corrected milk (kg/day) | ND        | 4.6 ± 0.3     | 3.9 ± 0.1        | ND              | 4.4 ± 0.3        | 4.1 ± 0.2        | 0.9259 | 0.0173 | 0.4071 |
| Protein energy corrected milk (kg/day) | ND       | 2.7 ± 0.1     | 2.6 ± 0.05       | ND              | 2.9 ± 0.1        | 2.9 ± 0.04       | 0.0094 | 0.4941 | 0.5162 |
| Back fat thickness (cm)      | 0.41 ± 0.04   | 0.34 ± 0.03   | 0.17 ± 0.01      | 0.46 ± 0.07     | 0.44 ± 0.04      | 0.21 ± 0.01      | 0.0411 | <0.0001 | 0.6893 |
| Glucose (mmol/L)             | 6.90 ± 0.45   | 4.48 ± 0.34   | 6.35 ± 0.48      | 5.67 ± 0.5      | 5.5 ± 0.42       | 5.28 ± 0.68      | 0.3038 | 0.0359 | 0.0359 |
| NEFA (mmol/L)                | 0.33 ± 0.05   | 1.54 ± 0.11   | 0.51 ± 0.14      | 0.25 ± 0.06     | 1.43 ± 0.42      | 0.96 ± 0.24      | 0.5735 | <0.0001 | 0.2519 |
| BHBA (mmol/L)                | 0.42 ± 0.01   | 1.31 ± 0.03   | 0.41 ± 0.02      | 0.35 ± 0.01     | 1.16 ± 0.11      | 0.40 ± 0.02      | 0.0291 | <0.0001 | 0.2549 |
| Insulin (ng/ml)              | 0.2 ± 0.02    | 0.11 ± 0.04   | 0.11 ± 0.03      | 0.31 ± 0.12     | 0.21 ± 0.11      | 0.25 ± 0.08      | 0.0541 | 0.4968 | 0.8701 |
| Leptin (ng/ml)               | 1.57 ± 0.04   | 0.74 ± 0.03   | 0.81 ± 0.01      | 1.66 ± 0.08     | 0.98 ± 0.06      | 1.22 ± 0.10      | <0.0001 | <0.0001 | 0.0160 |
| Adiponectin (µg/ml)          | 5.04 ± 0.26   | 2.79 ± 0.18   | 4.68 ± 0.16      | 5.26 ± 0.19     | 2.59 ± 0.2       | 6.12 ± 0.37      | 0.0134 | <0.0001 | 0.0025 |
| Resistin (ng/ml)             | 41.82 ± 1.71  | 71.28 ± 1.35  | 31.82 ± 0.7      | 41.56 ± 2.39    | 63.79 ± 2.27     | 29.69 ± 0.56     | 0.0139 | <0.0001 | 0.0701 |

1 Results are presented as mean ± SEM. p-values of the effects of NEB level at 1 WPP, time and interaction between NEB and time were considered significant if p-value < 0.05. With a,b and c the difference intra group and A, B the difference inter groups. Bold values represents significant values. ND, Not Determined.
Materials and methods

Ethical issues

All experimental procedures were approved by an Ethics Committee (Comité d’Ethique en Expérimentation Animale Val de Loire, CEEA VdL, protocol reference number 2012-10-4) and were consistent with the guidelines provided by the French Council for Animal Care.

Animals, experimental design and tissue collection

The study took place at the experimental unit UEPAO (Unité Expérimentale de Physiologie Animale de l’Orfisserie, Institut national de recherche pour l’agriculture, l’alimentation et l’environnement, Nouzilly, France).

From a herd of 39 Holstein heifers, two sub-groups of animals were selected with low negative energy balance (LNEB, \( n = 8 \)) and high negative energy balance (HNEB, \( n = 13 \)) according to their energy balance (EB) at 1 week postpartum [WPP, EB \( > -9 \) Mcal/day for LNEB and EB \( < -9 \) Mcal/day for HNEB (42)] and to their plasma BHBA concentrations at 1 WPP [BHBA \( < 1.2 \) mmol/L for LNEB and BHBA \( > 1.2 \) mmol/L for HNEB (11)]. Animals in the LNEB group were fed with a diet calculated to yield 35 kg of milk/cow/day and animals in the HNEB group were fed with a diet calculated to yield 25 kg of milk/cow/day (13). The diet composition for the LNEB group was: corn silage (61.2%), lucerne hay (10.1%); grass silage (0%), energy concentrate (17.2%), protein concentrate (10.7%), Ca carbonate (0.5%) and minerals (0.3%) whereas those of HNEB was: corn silage (50.4%), lucerne hay (10.2%); grass silage (24%), energy concentrate (8.5%), protein concentrate (6%), Ca carbonate (0.4%) and minerals (0.5%). Animals were reared in the same straw-bedded yard and the calving took place during the same period. The initial weight at 4 weeks before calving [4 weeks antepartum (4 WAP)] was 687.44 ± 18.91 kg for LNEB and 658.85 ± 18.34 kg for HNEB animals (Table 1). Blood samples and subcutaneous adipose tissue biopsies from cows were performed 4 WAP, 1 and 16 WPP (Figure 1). Cows were observed on their general condition in relation to feed intake, weariness, milk production and mammary infections every day; no clinical signs were apparent and no preventive medication was provided. Animals were routinely vaccinated against ovine catarhal fever at 5 months of age with two injections 3–4 weeks apart and another 12 months later. During the dry period, cows were also vaccinated against neonatal diarrhea in calves (enrichment of colostrum). All the animals were artificially inseminated and propylene glycol was distributed at the beginning of lactation to avoid ketosis.

Energy balance, dry matter intake, live body weight, variation in empty body weight, milk yield and back fat thickness

One month before the presumed calving date, animals were kept in a place not equipped with defined feeders so it was not possible to determine EB during this period, thus, EB was only calculated from calving to 16WPP. The EB was calculated per week according to the INRA feeding system (INRA, 2007) as the difference between energy intake and energy requirements for maintenance and milk production. The dry matter intake (DMI) was estimated from the DM content of the feed and the intake of fresh matter as measured automatically through a unique passive transponder attached to the ear tag and automatic feeders (RIC software, version RW1.7, Incentec, Marknesse, the Netherlands). Cows were milked twice a day and were automatically weighed after each milking (software RIC version RW1.7, Hokofarm Group, Marknesse, The Netherlands), and milk yield (MY) of each cow was automatically recorded through electronic collars (software R-Manufeed 500 pro, vc5 version 2.011.14, 1996, Manus-Delaval, Elancourt, France). Energy-corrected milk (ECM, 4% fat, 3.3% protein) was calculated according to the following equation: \( \text{ECM} = (\text{milk production} \times 0.383 \times \text{fat} \% + \text{milk production} \times 0.242 \times \text{protein} \% + 0.7832 \times \text{milk production}/3.1138) \). Live body weight (LBW)

![Figure 1](https://frontiersin.org)
was measured only during the morning milking to avoid the variation of body weight that occurs during the afternoon. LBW is affected by digestive contents so empty body weight (EBW) was estimated and corrected for digestive tract content, as described in Mellouk et al. (13). Adipose tissue mobilization was assessed through subcutaneous fat thickness measurements in the sacral region using ultrasonographic examination with a linear probe (LA 332 3.5/10.0-MHz transducer; Mylab30vet; R-Easote, Hospimedi, Saint-Crépin-Ibouvillers, France). Back fat thickness (BFT) was measured 4 WAP, 1 WPP and 16 WPP.

**Adipose tissue biopsies**

Subcutaneous adipose tissue biopsies were carried out 4WAP, 1 WPP and 16 WPP. Cows were fasted for 12 h before surgery and sedation was induced by intravenous injection of 12–14 mg of Xylazine (Rompun®, Bayer, Leverkusen, Germany) and subcutaneous injection of 20 mg of Lidocaine (Lurocaine®, Vetoquinol, Lure, France). Subcutaneous adipose tissue was collected from the dewlap under the neck, immediately frozen in liquid nitrogen and stored at −80°C until assay.

**Plasma biochemical parameters**

Blood samples were collected from the coccygeal vein into heparinized vacutainers (Dutcher, Brumath, France) at 4WAP and 1 and 16 WPP (Figure 1). Blood was immediately centrifugated at 2,000 g for 15 min at 4°C and plasma was stored at −20°C until assay. NEFA, BHBA and glucose plasma concentrations were determined by enzymatic colorimetry assays (Wako Chemicals GmbH, Neuss, Germany; Randox Laboratories Ltd., Antrim, United Kingdom and Sigma Aldrich, Saint-Quentin-Fallavier, France, respectively). The intra and interassay coefficients of variation of plasma NEFA, BHBA and glucose measures were 6 and 7.8%, 4 and 6%, and 6 and 8%, respectively. Plasma insulin was measured by radio immunoassay (RIA) from 100 µL of undiluted plasma as described in Mellouk et al. (13).

Plasma bovine resistin, total adiponectin and leptin concentrations were determined with commercial bovine ELISA kits according to the manufacturer’s protocol as described by Mellouk et al. (13). The sensitivity and the coefficient of variation of each ELISA kit used are indicated in Table 2.

Commercially available bovine ELISA kits (Table 2) were used to quantify plasma concentrations of FNDC3A, FNDC3B, FNDC4 and FNDC5 at 4WAP, 1 WPP and 16 WPP. Samples were run in duplicate within the same assay. The sensitivity and the coefficient of variation of each ELISA kit used are indicated in Table 2.

**RNA extraction and RT-qPCR**

Total RNA was extracted on ice from 30 mg of tissue with an Ultraturrax T25 Basic IKA Labortechnik homogenizer (Amilabo, Chassieu, France) in 1 ml of QIAzol lysis reagent (Qiagen, Courtaboeuf, France). One hundred microliter of chloroform (VWR chemicals, France) were added to each lysate. The samples were vortexed for 10 seconds then centrifuged for 15 min at 13,300 rpm at 4°C. The aqueous phase was recovered and then mixed with 500 µl of isopropanol (Carlo Erba Reagent, France), and placed on ice for 10 min before centrifugation (10 min at 13,300 rpm at 4°C). The supernatant was removed and the pellet was resuspended in 1 ml of 75% ethanol (diluted from absolute ethanol, Carlo Erba, France) then the samples were vortexed and centrifuged for 5 min at 8,800 rpm at 4°C. The supernatant was removed, and the pellet was air-dried, and resuspended in 40 µl of sterile demineralized water. DNAse treatment (NucleoSpin® RNA Plus, Macherey-Nagel, France) was applied to the samples and the quantity and the quality of RNA was determined with a NanoDrop 2000 spectrophotometer (Thermo Scientific, USA).

The cDNAs were generated by reverse transcription (RT) of total RNA (1 µg) in a mixture with 0.5 mM of each deoxyribonucleotide triphosphate (dATP, dGTP, dCTP, dTTP), 2 M of RT buffer, 15 µg/µl of oligodT primer, 0.125 U of ribonuclease inhibitor (Recombinant RNasin® Ribonuclease Inhibitor) and 0.05 U of M-MLV (Moloney Murine Leukemia

### Table 2: List of ELISA assays used for measurement of bovine plasma FNDC concentration.

| Protein         | Supplier                        | Species | Assay sensitivity (ng/ml) | Coefficient of variation (%) |
|-----------------|---------------------------------|---------|--------------------------|-----------------------------|
| Resistin        | USCNLife/ CLOUD Clone Corps. (E90847Bo) | Bovine  | 0.031                    | 6.0                         |
| Total adiponectin | Holzel (E11A0125)                | Bovine  | 0.1                      | <8.0                        |
| Leptin          | Holzel (E11L0038)                | Bovine  | 0.1                      | <8.0                        |
| FNDC3A          | MyBioSource (Cat. MBS7201899-96) | Bovine  | 1.0                      | <10                         |
| FNDC3B          | MyBioSource (Cat. MBS7211809-96) | Bovine  | 1.0                      | <10                         |
| FNDC4           | MyBioSource (Cat. MBS7221653-96) | Bovine  | 0.1                      | <10                         |
| FNDC5           | MyBioSource (Cat. MBS7246743-96) | Bovine  | 0.1                      | <10                         |
TABLE 3  Nucleotide primer sequences used for real time RT-PCR.

| Gene   | Species | Product length (pb) | Forward | Reverse | Number of accession | Efficiency |
|--------|---------|---------------------|---------|---------|---------------------|------------|
| PPIA   | bov     | 216                 | 5′-GCTACAGTTCCTGCATCT-3' | 5′-TGTCCACAGTCGCAATGTT-3' | NM_178320.2 | 1.9         |
| PPIA   | hum     | 161                 | 5′-GGCAATCTGGTGAACAAACA-3' | 5′-TGGGTCGCCGATCCTCGGA-3' | NM_021130  | 2.0         |
| SDHA   | bov     | 168                 | 5′-TATATCGGGCTGCGTCTC-3' | 5′-CCCTTCTCCCGGCGATTTTC-3' | NM_174782.2 | 2.0         |
| SDHA   | hum     | 279                 | 5′-GAAGGTCCTCGGATGATA-3' | 5′-CTGAGGGTGAAGCTGAC-3' | NM_001468.1 | 1.9         |
| UXT    | bov     | 111                 | 5′-CTGGAGGATCGCCAGAGAAG-3' | 5′-GCCCAATAGATGTCGTGAGA-3' | NM_00103747.2 | 1.9         |
| UXT    | hum     | 80                  | 5′-AGTGCTCGCTAGGACAGACT-3' | 5′-ATACCTTGCTGATGGTCCC-3' | NM_153477.3 | 1.8         |
| FNDC3A | bov     | 99                  | 5′-TAAGTGCAGATGGAACACACAG-3' | 5′-CTGTAATGCACTGAAACTGCCA-3' | NM_00120566.1 | 2.0         |
| FNDC3B | bov     | 135                 | 5′-ATGCTCAGTTGTAATGAGG-3' | 5′-CATCAGGGAACTTCAGCAGGT-3' | NM_00120621.2 | 2.0         |
| FNDC4  | bov     | 148                 | 5′-GGAACCTGTAGTCCGAGAG-3' | 5′-AGAATCGGAAGTGACACCT-3' | NM_00101234.1 | 2.0         |
| FNDC5  | bov     | 187                 | 5′-GTTAAGCGTGGAGTCTGAG-3' | 5′-CTGACCCTTCGATTGATGG-3' | NM_00105421.2 | 2.0         |
| ITGAV  | bov     | 183                 | 5′-TTCGGCATTCTATGAAAGG-3' | 5′-AGGCGACGGCCAGTGTAT-3' | NM_174637.1 | 2.0         |
| ITGB1  | bov     | 231                 | 5′-TGAGGCTAAAGCAGAAGACA-3' | 5′-TGCACCTACACACTGCA-3' | NM_174638.3 | 2.0         |
| ADGRF5 | bov     | 189                 | 5′-TATCGTGAAGTTCGCTCAG-3' | 5′-TCTGACGTCAACAACCACT-3' | NM_00119324.1 | 2.0         |
| ATGL   | bov     | 130                 | 5′-AAGGCTGCGACAACATCAT-3' | 5′-TAGGATCAGGGGCAAGAAT-3' | NM_00146050.2 | 2.0         |
| HSL    | bov     | 199                 | 5′-GAGAATTGGAGCATTGCTGAC-3' | 5′-TGCTGACAGGAGCTGACCT-3' | NM_00100820.1 | 2.0         |
| ATGL   | hum     | 119                 | 5′-GTCGACAGGGGAGGAATG-3' | 5′-TGGAGGAGGAGGAGGATG-3' | NM_021576.4 | 2.0         |
| HSL    | hum     | 298                 | 5′-GTCGAAAGACGGAGGAGCATCCA-3' | 5′-GACGTCTCGAGGATTTCCCCAGT-3' | NM_005357.4 | 1.9         |

Cat, human; bov, bovine.

Virus) Reverse Transcriptase (Promega, Charbonnières-les-Bains, France) and incubated for 1 h at 37°C. The qPCR was carried out using the MyiQ Cycle device (Bio-Rad, Marnes-la-Coquette, France) in a mixture of SYBR Green Supermix 1X reagent (Bio-Rad, Marnes-la-Coquette, France), 250 nM specific primers (Invitrogen by Life Technologies, Villebon-sur-Yvette, France; Table 3). For each gene, relative abundance was calculated according to primer efficiency (E) and quantification cycle (Cq), where expression = E−Cq. Melting curve analysis were performed to verify the presence of a single amplicon. The expression of the target gene was expressed relative to the geometric mean of three specific reference genes, peptidylprolyl isomerase A (PPIA), succinate dehydrogenase complex flavoprotein subunit A (SDHA), and ubiquitously expressed prefoldin like chaperone (UXT) previously validated and that were not affected by the physiological status and the EB level (42, 43). Same housekeeping genes were used for all samples except for HSL and ATGL where Cyclophilin A (PPIA), GAPDH and β-actin were used as reference gene. The geometric mean of housekeeping genes has been reported as an accurate normalization factor (43).

To survey FNDC mRNA abundance in a variety of tissues, samples of bovine pituitary, kidney, skeletal semitendinosus muscle, liver, heart, and subcutaneous adipose tissue were collected from a local slaughterhouse within 30 min after sacrifice and frozen in liquid nitrogen before extraction of RNA.

Protein extraction and western blot

Tissues were lysed using Ultraturrax T25 Basic IKA Labortechnik (Amilabo, Chassieu, France) in lysis buffer [1 M Tris (pH 7.4), 0.15 M NaCl, 1.3 mM EDTA, 1 mM EGTA, 23 mM VO₄³⁻, 0.1 M NaF, 1% NH₄PO₄, 0.5% Triton). The lysates were centrifuged for 20 min at 13,300 rpm at 4°C and the supernatant containing the proteins was collected and stored on ice. Protein concentration was measured using the Bicinchoninic Acid Protein Assay (BCA; Interchim, Montluçon, France). The protein lysates (40 µg) were mixed with 5X Laemmli buffer and the proteins were denatured for 5 min by heat shock at 95°C. The proteins were loaded into a 15% sodium dodecyl sulfate-polyacrylamide gel, and after electrophoresis the proteins were transferred from the gel to a nitrocellulose membrane. The membranes were blocked with 0.05% Tween 20 and 5% powdered cow’s milk in Tris-saline buffer for 30 min at room temperature. The membranes were then incubated overnight...
TABLE 4 List of antibodies used for the detection of proteins by Western blot.

| Primary antibodies | Dilution | Supplier | Host | Molecular weight (kDa) |
|---------------------|----------|----------|------|------------------------|
| β-actin             | 1:1000   | Sigma    | Rabbit | 42                     |
| Irisin (42–112)     | 1:1000   | Phoenix Pharmaceuticals, Inc | Rabbit | 25 and 12.6            |
| Vinculin            | 1:200    | Sigma-Aldrich | Mouse | 110                   |

Secondary antibodies

| Secondary antibodies | Dilution | Supplier | Host |
|----------------------|----------|----------|------|
| Anti-mouse           | 1:5000   | Millipore | Goat |
| Anti-rabbit          | 1:5000   | Biorad   | Goat |

at 4°C with the appropriate primary antibody (Table 4). The anti-irisin (12.6 kDa) antibody also recognizes FNDC5 with a molecular weight of ~25 kDa (44). The membranes were then incubated for 90 min at room temperature with a HorseRadish Peroxidase-conjugated (HRP) anti-rabbit IgG secondary antibody (Table 4). The proteins of interest were detected by enhanced chemiluminescence (Western Lightning Plus-ECL, Perkin Elmer, Yvelines, France), with a G: Box Syngene (Ozyme) and GeneSnap software (version 7.09.17), Ozyme. Signal intensity was quantified with the GeneTools software, and the results expressed relative to β-actin or vinculin.

Adipose tissue explant culture

Abdominal adipose tissue was collected from 6 dairy cows at a local slaughterhouse immediately after death, and was transported to the laboratory at 37°C in DMEM supplemented L-glutamine (PAA Laboratories GmbH, Cölbe, Germany). For each animal, the tissue (200 mg) was cut into 10 small pieces under sterile conditions and incubated in quadruplicate with 250 µl of DMEM supplemented with penicillin/streptomycin and amphotericin with increasing doses of human recombinant irisin (0, 0.1, 1 and 10 ng/ml) for 24 h at 37°C under an atmosphere containing 5% CO₂. The tissue explants and the culture medium were then collected and immediately stored at −20°C.

Human abdominal subcutaneous adipose tissue was collected from patients (n = 6) undergoing bariatric surgery and included in the prospective monocentric METABOSE cohort (Nutrition Department, CHU Tours) following patient written consent and after local ethical committee agreement (CNIL no. 18254562). Once collected, adipose tissue explants were prepared and were cultured under the same conditions as bovine adipose tissue explants as described above.

In vitro lipolysis assay

The rate of lipolysis in the adipose tissue explants was determined by measuring glycerol release into the incubation medium (Sigma, St. Louis, MO, USA) and by quantifying abundance of mRNA encoding HSL and ATGL.

Statistical analysis

All statistical analyses were performed with GraphPad Prism 6 software. Data were tested for homogeneity of variance by Bartlett’s test and for normal distribution by Shapiro-Wilk test. A two-way analysis of variance (ANOVA) with repeated measures was carried out to determine effects of time and NEB level at 1 WPP (LNEB vs. HNEB) on endpoints measured. Furthermore, the interaction, NEB level at WPP and the time was also analyzed. A Sidak correction was applied to multiple comparisons. A one-way analysis of variance (ANOVA) was carried out to analyse gene and protein expression in metabolic tissues and lipolysis. A Tukey correction was applied to multiple comparisons. A unidirectional non-parametric analysis of variance (Friedman test) with repeated measures was carried out to analyse plasma FNDC concentrations and protein expression in adipose tissue in each group and gene expression in adipose tissue of both groups. A Dunn correction was applied to multiple comparisons. The correlation between physiological (zootchnical, plasma metabolites and metabolic hormones) parameters and FNDC mRNA abundance with plasma concentrations were investigated by using Spearman correlations. All experimental data are presented as means ± SEM. The level of statistical significance was set at p < 0.05.

Results

Energy balance, live body weight, variation empty in body weight, milk yield, energy corrected milk, dry matter intake and fat back thickness

Live body weight, variation of empty body weight (VEBW), and back fat thickness (BFT) were measured at 4 WAP, 1 and 16 WPP and energy balance (EB), dry matter intake (DMI), milk yield (MY) and fat and protein energy corrected milk (ECM) were measured at 1 and 16 WPP in both LNEB and
HNEB animals. As described above, LNEB and HNEB groups were determined according to the EB at 1 WPP (−5.60 ± 0.77 Mcal/day for LNEB and −12.16 ± 0.53 Mcal/day for HNEB) and to their plasma BHBA concentrations at 1 WPP (mean ± SEM for LNEB and HNEB group: 1.16 ± 0.11 mmol/L and 1.31 ± 0.03 mmol/L, respectively; Table 1). For all the zootechnical parameters studied except for protein ECM, we observed a significant effect of peripartum time and a significant difference between LNEB and HNEB animals except for MY, fat ECM and VEBW (Table 1).

### Plasma glucose, NEFA, BHBA and insulin

To assess mobilization of adipose tissue and ketogenesis, plasma NEFA and BHBA were measured, respectively. There was a significant effect of NEB status at 1WPP on BHBA but not on NEFA plasma concentrations. However, there was a significant time effect with an increase of NEFA and BHBA plasma concentrations at 1 WPP as compared to 4 WAP for both HNEB and LNEB animals and at 1 WPP as compared with 16 WPP for only HNEB animals. At 1WPP, BHBA plasma concentrations were higher in HNEB than in LNEB animals (Table 1). Plasma glucose concentrations were affected by peripartum time only in HNEB group with a decrease at 1 WPP as compared with 4 WAP and 16 WPP (Table 1). There was no significant effect of either NEB status at 1 WPP or peripartum time on plasma insulin concentrations.

### Plasma concentration of adiponectin, leptin and resistin

Plasma concentrations of adiponectin, leptin and resistin were significantly affected by both NEB level at 1 WPP and peripartum time (Table 1). Plasma leptin concentrations decreased at 1 and 16 WPP as compared to 4WAP, and were significantly lower in HNEB group than in LNEB group post-partum. Plasma adiponectin concentrations decreased at 1WPP compared to 4WAP and increased at 16WPP to levels not different from 4WAP; adiponectin concentrations were higher in LNEB than in HNEB animals.
TABLE 5  Plasma FNDC3A, FNDC3B, FNDC4 and FNDC5 concentrations in HNEB and LNEB animals at 4 WAP and 1 and 16 WPP.

| FNDC      | HNEB Mean ± SEM | LNEB Mean ± SEM | p-Value   |
|-----------|-----------------|-----------------|-----------|
| FNDC3A (ng/ml) | 30.68 ± 3.39    | 32.97 ± 6.49    | 0.0001    |
| FNDC3B (ng/ml) | 70.92 ± 3.04    | 69.63 ± 3.87    | 0.044     |
| FNDC4 (ng/ml)  | 16.90 ± 2.45    | 19.20 ± 5.06    | 0.029     |
| FNDC5 (ng/ml)  | 7.23± 0.51      | 4.55± 0.52      | 0.05     |

Data are mean ± SEM and were analyzed by two-way analysis of variance (ANOVA). The results were considered significant if p-value <0.05. Bold values represents significant values. Groups with different letters are significantly different (p < 0.05).

TABLE 6  Spearman correlation coefficients (r) between FNDC plasma concentration and zootechnical parameters and plasma metabolites and hormones in both LNEB and HNEB animals during the peripartum period (4WAP–16WPP).

| Parameter                          | Plasma FNDC5 |
|------------------------------------|--------------|
| Energy balance (EB, Mcal/day)      | r = 0.359    |
| p-value                            | 0.012        |
| Dry matter intake (DMI, kg/day)    | r = 0.313    |
| p-value                            | 0.044        |
| Live body weight (LBW, kg/day)     | r = 0.364    |
| p-value                            | 0.012        |
| Variation of empty body weight     | r = 0.496    |
| (VEBW, kg/day)                     | p-value 3.9×10⁻⁴ |
| Milk Yield (MY, kg/day)            | r = 0.126    |
| p-value                            | 0.491        |
| Back fat thickness (BFT, cm)       | r = 0.137    |
| p-value                            | 0.360        |
| Fat energy corrected milk (kg/day) | r = 0.29     |
| p-value                            | 0.875        |
| Protein energy corrected milk (kg/day) | r = 0.033 |
| p-value                            | 0.856        |
| Glucose (mmol/L)                   | r = 0.344    |
| p-value                            | 0.018        |
| NEFA (mmol/L)                      | r = 0.610    |
| p-value                            | 5.4×10⁻⁴     |
| BHBA (mmol/L)                      | r = 0.731    |
| p-value                            | 7.9×10⁻⁴     |
| Insulin (ng/ml)                    | r = 0.696    |
| p-value                            | 3.4×10⁻⁴     |
| Leptin (ng/ml)                     | r = 0.349    |
| p-value                            | 0.027        |
| Adiponectin (µg/ml)                | r = 0.655    |
| p-value                            | 7.8×10⁻⁷     |
| Resistin (ng/ml)                   | r = 0.162    |
| p-value                            | 0.288        |

Correlations were considered significant if p-value <0.05. Bold values represents significant values.

Plasma concentration of FNDCs and association of plasma FNDC5 concentrations with other metabolic parameters

By using specific bovine ELISA assays, we investigated plasma concentration of FNDC3A, FNDC3B, FNDC4 and FNDC5 at 4 WAP, and at 1 and 16 WPP in LNEB and HNEB animals. We did not observe any difference between LNEB and HNEB animals for all FNDCs. There were no significant changes in FNDC3A, FNDC3B and FNDC4 concentrations during the peripartum period, whereas plasma FNDC5 concentrations were significantly higher at 1 WPP compared with 4 WAP and 16 WPP in both group (p-value: 0.00179 in LNEB group and p-value: <0.0001 in HNEB group; Figure 2 and Table 5).

We next determined potential correlations between plasma FNDC5 concentrations and zootechnical parameters, plasma metabolites and hormones by combining data from HNEB and LNEB animals during the period 4WAP to 16 WPP. As shown in Table 6, plasma FNDC5 concentrations were negatively correlated with DMI, LBW, VEBW, glucose and insulin levels, and were positively associated with plasma NEFA, BHBA, leptin and adiponectin concentrations.

FNDC and receptor expression in tissues

We next investigated gene expression of FNDCs and FNDC4 and five receptors (ADGRF5, ITGAV and PITGB1) at the
mRNA level in various bovine tissues. As shown in Figure 3, abundance of FNDC3A, FNDC3B and ITGAV mRNA was similar in all tissues studied. The abundance of ADGRF5 mRNA was higher in skeletal muscle compared with the other tissues, and ITGB1 mRNA was most abundant in the kidney \( (p < 0.05) \). Messenger RNA encoding FNDC5 was most abundant in subcutaneous adipose tissue as compared to the other tissues and mRNA encoding FNDC4 was more expressed in kidney and heart than in subcutaneous adipose tissue and pituitary.

Using a commercial human anti-irisin antibody, we confirmed the higher expression of FNDC5 protein \((25 \text{ kDa})\) in bovine subcutaneous adipose tissue and heart compared with pituitary and kidney \( (\text{Figure 4A} \). This antibody did not detect cleaved irisin \((\text{expected mass 12.6 kDa})\) in bovine or human adipose tissue \( (\text{Figure 4B} \).

**FNDCs and receptor expression in subcutaneous bovine adipose tissue during peripartum in LNEB and HNEB animals**

We next determined gene expression of FNDC3A, FNDC3B, FNDC4, FNDC5, ADGRF5, ITGAV and ITGB1 in subcutaneous adipose tissue biopsies at 4 WAP, 1 WPP and 16 WPP in LNEB and HNEB animals. There was no significant difference between LNEB and HNEB animals for all the genes studied except for FNDC5 mRNA \( (\text{Table 7}) \), therefore we combined the two groups of animals for these genes and analyzed the effect of peripartum time \( (\text{Figures 5A–G}) \). Abundance of FNDC3B \( (\text{Figure 5B}) \) and FNDC4 \( (\text{Figure 5C}) \) mRNA was significantly higher at 1WPP as compared with both 4WAP and 16 WPP, whereas FNDC3A \( (\text{Figure 5A}) \) and ITGB1 \( (\text{Figure 5F}) \) mRNA abundance was significantly higher at 1WPP compared with...
Protein expression of FNDC5 in different bovine tissues. (A) Abundance of FNDC5 protein was determined by western blot in tissues obtained from an abattoir. A representative blot is shown above the means. Data are expressed as mean ± SEM for each group (n = 7) and analyzed by one-way analysis of variance (ANOVA). (B) Bovine (n = 5) and human (n = 4) abdominal subcutaneous adipose tissues were examined for full-length (25 kDa) and cleaved (12 kDa) forms of FNDC5/irisin.

TABLE 7  Relative gene expression of FNDC3A, FNDC3B, FNDC4, FNDC5, ITGAV, ITGBI and ADGRF5 in LNEB and HNEB animals during the peripartum period (1WAP, 1 and 16WPP).

| Gene     | HNEB 4 WAP Mean ± SEM | HNEB 1 WPP Mean ± SEM | HNEB 16 WPP Mean ± SEM | LNEB 4 WAP Mean ± SEM | LNEB 1 WPP Mean ± SEM | LNEB 16 WPP Mean ± SEM | p-Value NEB level x Time |
|----------|------------------------|------------------------|-------------------------|------------------------|------------------------|------------------------|---------------------------|
| FNDC3A   | 0.89b ± 0.45           | 4.28a ± 1.79           | 0.17a ± 0.06            | 0.34b ± 0.23           | 1.36a ± 1.26           | 0.18b ± 0.12           | 0.21                       |
| FNDC3B   | 2.93a ± 1.24           | 38.15b ± 13.85         | 7.38b ± 4.42            | 2.57a ± 1.9            | 24.44a ± 15.35         | 0.76b ± 0.48            | 0.35                       |
| FNDC4    | 1.03a ± 0.29           | 8.39b ± 1.55           | 1.88a ± 0.82            | 0.76a ± 0.32           | 8.11a ± 2.66           | 0.38b ± 0.09            | 0.81                       |
| FNDC5    | 0.38a ± 0.07           | 1.42b ± 0.18           | 0.64a ± 0.16            | 0.24a ± 0.08           | 0.86a ± 0.23           | 0.35a ± 0.08            | 0.002                      |
| ITGAV    | 0.44a ± 0.11           | 0.5 ± 0.34             | 0.11a ± 0.05            | 0.57a ± 0.27           | 0.17b ± 0.19           | 0.08b ± 0.06            | 0.59                       |
| ITGBI    | 31.54a ± 18.21         | 35.86a ± 16.71         | 1.42 ± 0.56             | 0.73a ± 0.22           | 0.05 ± 0.01            | 1.51 ± 2.14             | 0.27                       |
| ADGRF5   | 1.08a ± 0.28           | 3.73a ± 1.15           | 0.32a ± 0.12            | 0.94a ± 0.87           | 0.52a ± 0.37           | 0.25a ± 0.25            | 0.08                       |

Gene expression was determined by real-time RT-qPCR. Data are Mean ± SEM. The results were considered significant if p-value < 0.05.

Results are presented as Mean ± SEM. p-values of the effects of NEB level at 1 WPP, time and interaction between NEB and time were considered significant if p-value < 0.05. With a and b the difference intra group and A, B the difference inter groups. Bold values represents significant values.

The abundance of ADGRF5 mRNA (Figure 5D) was lower at 16 WPP compared to both 4 WAP and 1 WPP whereas that of ITGAV (Figure 5G) was higher at 4 WAP compared with 16WPP and 1WPP. Abundance of FNDC5 mRNA was significantly increased at 1WPP compared to 4WAP and 16WPP in the HNEB group and significantly increased at 1WPP as compared to 4WAP only in the LNEB group. FNDC5 mRNA abundance was higher in HNEB compared with LNEB animals 1WPP (Figure 5E, Table 7).

We did not observe any variation of FNDC5 protein (25 kDa) abundance in bovine subcutaneous adipose tissue during the peripartum period or between NEB level (Figure 6).

We next determined potential correlations between adipose FNDC mRNA abundance and plasma FNDC concentrations.
Abundance of FNDC3A (A), FNDC3B (B), FNDC4 (C), FNDC5 (E), ITGAV (G), ITGB1 (F) and ADGRF5 (D) mRNA in bovine subcutaneous adipose tissue during peripartum period. Tissues were obtained 4 weeks before parturition (4WAP) and 1 (1WPP) and 16 weeks post-partum (16WPP) and mRNA measured by real-time RT-qPCR. Data are expressed as mean ± SEM for each group (n = 8 in LNEB group and n = 13 in HNEB group) and analysed by a nonparametric analysis of variance with repeated measures (Friedman test). Groups with different letters are significantly different (p < 0.05). * indicates a significant difference (p < 0.05).

Only plasma FNDC5 concentrations was positively correlated with FNDC5 mRNA abundance (Table 8). Plasma FNDC3A, FNDC3B and FNDC4 concentrations were not significantly correlated with their respective adipose tissue mRNA expression (Table 8).

Effect of recombinant human irisin on the release of glycerol and on adipose triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL) mRNA abundance in bovine and human subcutaneous adipose tissue explants

Since plasma FNDC5 concentrations and adipose FNDC5 mRNA abundance were higher at 1 WPP when the adipose tissue mobilization was greatest, we determined whether irisin could be involved in adipose tissue lipolysis. Human recombinant irisin significantly increased glycerol release (Figure 7A) and HSL (Figure 7B) and ATGL (Figure 7C) mRNA abundance in a dose-dependent manner in both bovine and human adipose tissue explants (Figures 7D–F).

Discussion

This study provides several lines of evidence that the myokine/adipokine FNDC5/irisin plays a role in adipose tissue mobilization during post-partum negative energy balance in dairy cattle. First, both plasma concentrations of FNDC5/Irisin and FNDC5 gene expression in adipose tissue increased 1 week after calving during NEB, compared to 4 weeks before and 16 weeks after calving. Second, recombinant irisin, which is the cleaved and secreted fragment of FNDC5, increased the release of glycerol and ATGL and HSL mRNA abundance in bovine and human adipose tissue explants, thus directly stimulating adipose tissue lipid mobilization.
In our present study, we detected greater abundance of FNDC5 mRNA and protein in subcutaneous adipose tissue compared with skeletal muscle. This discrepancy is not easy to explain, but may be related to site of tissue sampling [semitendinosus muscle in our study vs. longissimus muscle in Komolka et al. (51)], sex of the individual [male cattle in (51)] or breed (dairy vs. beef cattle). In humans, a sexual dimorphism in irisin concentrations at rest has been described with a higher concentration in girls vs. boys (52) and in women vs. men (53). In rats, low-oxidative fiber-type muscle (soleus) secretes ∼40% more FNDC5/irisin than fast-glycolytic fiber-type muscle (gastrocnemius) (48). Western blot experiments demonstrated
FIGURE 7
Effect of human recombinant irisin on the release of glycerol and on HSL and ATGL mRNA abundance from bovine (A–C) and human adipose tissue explants (D–F), n = 6 for each species. (A,D) Data are expressed as millimoles per 200 mg of tissue per hour ± SEM and different letters indicate significant difference at p < 0.0001. (B,E) ATGL mRNA and (C,F) HSL mRNA abundance in adipose tissue explants incubated with increasing doses of human recombinant irisin (0, 0.1, 1 and 10 ng/ml, n = 6). Abundance is expressed relative to the geometric mean of three reference genes (Cyclophilin A (PPIA), GAPDH and β-actin) and analyzed by one way analysis of variance (ANOVA). Data are presented as mean ± SEM. Different letters indicate significant differences at p < 0.0001.

the presence of the full-length transmembrane protein (∼25 kDa) and not the cleaved form (∼12.6 kDa), which is to be expected in tissue samples as the cleaved form would be released from the cell surface and presumably into the circulation. Our data are in a good agreement with those of Boström (32) and Roca-Rivada (48) who detected a predominant band of ∼25 kDa especially when using an anti-irisin antibody (anti-Irisin Phoenix Pharmaceuticals amino acids 42–112). As reported by Roca-Rivada et al. (48), the full length FNDC5/irisin is also probably secreted. To our knowledge, the release of the 12.6 kDa form of irisin from muscles or other tissues has not been reported so far.

It is known that the secretion of several adipokines changes during the NEB of early lactation, including resistin that increases and adiponectin that decreases at the onset of lactation (13, 17), and the present data show that members of the FNDC family are also affected. In the present study, abundance of adipose FNDC5 mRNA and plasma irisin/FNDC5 concentrations were increased during early lactation concomitant with increased plasma NEFA concentrations and adipose tissue mobilization. Plasma FNDC5 is correlated with FNDC5 mRNA levels and FNDC5 protein expression in adipose tissue during the peripartum period.

Generally, mRNA expression is assumed to be predictive of protein expression level. However, the correlation between mRNA and protein expression has been described as moderately or weakly positive (correlation coefficients ranging from 0.2 to 0.6), especially with regard to secreted proteins (54, 55). Our results illustrate this fact well. The question is now to understand what is the origin of the increase in plasma FNDC5 particularly at 1 WPP. We can hypothesize that the increase in plasma FNDC5 concentration is due to secretion from skeletal muscle but unfortunately we did not perform muscle biopsy in our protocol to verify this hypothesis. In our study, adipose FNDC5 mRNA abundance was higher in animals with a deeper negative energy balance 1 WPP. In human and rodent models, there is no clear association between nutrition and FNDC5 expression, as in some studies adipose FNDC5 mRNA abundance is increased by exercise and in lean compared with obese subjects (56), whereas plasma irisin concentrations decrease after rapid weight loss in some studies (56) but not in others (57). The lactating dairy cow is an example of sudden changes in energy balance, and the increase in FNDC5 mRNA and plasma irisin/FNDC5 concentrations observed here may be an adaptive response to this NEB. This is supported by the present data showing that irisin increased lipolysis in bovine adipose tissue explants.
suggesting that irisin could be involved in fat mobilization. A similar effect was observed in human adipocytes (58) and in 3T3-L1 adipocytes (59, 60), although other studies have reported no effect or a decrease in lipolysis (61, 62). Resistin also increases lipolysis (9), suggesting that a number of adipokines are involved in the mobilization of reserves to meet the energy demands of early lactation.

Three other FNDC family members were shown to be altered during NEB in the present study, FNDC3A, FNDC3B and FNDC4. All three were found to be widely expressed in bovine tissues, although abundance of FNDC4 mRNA in adipose tissue was very low suggesting that this FNDC member is a myokine rather than an adipokine. Although mRNA abundance of all three was increased in adipose tissue during NEB, there were no changes in plasma concentrations. In humans, FNDC4 mRNA abundance in adipose tissue is higher in obese than in lean subjects whereas plasma FNDC4 concentrations are lower in obese patients (40); this, and the present data, suggests that adipose tissue is not a major contributor to plasma concentrations, and are consistent with the finding that the liver is the major source of circulating FNDC4 (63). The source of circulating FNDC3A and FNDC3B is unclear as these transmembrane proteins are not known to be cleaved and released as a secreted hormone; it is more likely that adipocyte (and other) cell death released membrane proteins into the circulation, and that this is not linked to adipose tissue mobilization during NEB.

In conclusion, the present data show that FNDC5 plasma concentrations and FNDC5 gene expression in adipose tissue are increased 1 week after calving when the mobilization of reserves is high. Furthermore, FNDC5 is expressed in dairy cow muscle and subcutaneous adipose tissue and irisin may enhanced lipid mobilization in bovine adipose explants. Thus, we can hypothesize that increased irisin is an adaptive response to NEB and serves to meet the energy demands of lactation in cattle.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by Comité d’Ethique en Expérimentation Animale Val de Loire, CEEA VdL. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by Comité d’Ethique en Expérimentation Animale Val de Loire, CEEA VdL. The studies were conducted in accordance with the guidelines and regulations of the experimental unit UEPAO.

Author contributions

MD and CR: methodology, validation, formal analysis, visualization, and writing—original draft.
AE: methodology and writing—review and editing.
CP: methodology, formal analysis, visualization, writing—review and editing, and supervision.
JD: methodology, validation, formal analysis, investigation, visualization, writing—review and editing, supervision, project administration, and funding acquisition. All authors contributed to the article and approved the submitted version.

Funding

This work was financially supported by INRAE and RQR (Réseau Québécois en Reproduction). The research leading to these results has received funding from the European Union Seventh Framework Programs (FP7: 2007-2013) under the grant agreement no. 311776 and from the Fonds de Recherche du Québec - Nature et Technologies, administered through the Réseau Québécois en Reproduction.

Acknowledgments

We thank Eric Briant, Mickael Dupont, Mickael Delanoue, Ludovic Métivier, and Christophe Mouaze of the Experimental Unit UEPAO for animal management and involvement in the experiment.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References

1. Roche JR, Burke CR, Crookenden MA, Heiser A, Loo JR, Meier S, et al. Fertility and the transition dairy cow. Reprod Fertil Dev. (2018) 30:858. doi: 10.1071/RF17412

2. Waikhalde PR, Mannamara AN, Kumasarz A, Jayakumar S, Ramesha KP, Sejan V, et al. Metabolic and immunological changes in transition dairy cows: a review. Vet World. (2017) 10:1367–77. doi: 10.14202/vetworld.2017.1367-1377

3. Stracke I, Mlynek K, Danielewicz A. The capacity of Holstein-Friesian and Simmental cows to correct a negative energy balance in relation to their performance parameters, course of lactation, and selected milk components. Animals. (2011) 11:1676. doi: 10.3390/an11061674

4. Kelly JM. Changes in serum B hydroxybutyrate concentrations in dairy cows kept under commercial farm conditions. Vet Rec. (1977) 101:499–502.

5. Chapinal N, Carson ME, LeBlanc SJ, Leslie KE, Godden S, Capel M, et al. The association of serum metabolites in the transition period with milk production and early-lactation reproductive performance. J Dairy Sci. (2012) 95:1301–9. doi: 10.3168/jds.2011-4742

6. Herdt TH. Ruminant adaptation to negative energy balance. Vet Clin North Am Food Anim Pract. (2000) 16:215–30. doi: 10.1016/S0749-0720(15)30102-X

7. Ospina PA, Nydam DV, Stokol T, Overton TR. Associations of elevated nonesterified fatty acids and B-hydroxybutyrate concentrations with early lactation reproductive performance and milk production in transition dairy cattle in the northeastern United States. J Dairy Sci. (2010) 93:1596–603. doi: 10.3168/jds.2009-2852

8. Sharma A, Baddela VS, Becker F, Dannenberger D, Viergutz T, Vanselow J. Elevated free fatty acids affect bovine granulosa cell function: a molecular cue for compromised reproduction during negative energy balance. Endocr Connect. (2019) 8:493–505. doi: 10.1530/EC-19-0011

9. Lucy M. Fertility in high-producing dairy cows: reasons for decline and corrective strategies for sustainable improvement. Reprod Dom Rum. (2007) 2:257–54. doi: 10.5661/RDR-VI-237

10. Esposito G, Irons PC, Webb EC, Chapwanya A. Interactions between negative energy balance, metabolic diseases, uterine health and immune response in transition dairy cows. Anim Reprod Sci. (2014) 144:69–71. doi: 10.1016/j.anireprosci.2013.11.007

11. Nielson M, Aarts MGA, Jonkers AGM, Wensing T, Schuiken VH. Evaluation of two cowide tests for the detection of subclinical ketosis in dairy cows. Can Vet J. (1994) 35:4.

12. Bauman DE, Bruce Currie W. Partitioning of nutrients during pregnancy and lactation: a review of mechanisms involving homoeostasis and homeoeosis. J Dairy Sci. (1998) 80:914–29. doi: 10.3168/jds.S0022-0302(98)73111-0

13. Mellouk N, Rame C, Touze JL, Briant E, Ma L, Guillaume D, et al. Involvement of plasma adipokines in metabolic and reproductive parameters in Holstein dairy cows fed with diets with differing energy levels. J Dairy Sci. (2017) 100:8516–33. doi: 10.3168/jds.2017-12657

14. Gassy SL, Yoon R, Currie WR, Kim JW, Boisclair YR. Adiponectin deficit during the precocious glucose economy of early lactation in dairy cows. Endocrinology. (2012) 153:5834–44. doi: 10.1210/en.2012-1176

15. Ohtani Y, Takahashi T, Sato K, Ardyanty A, Song SH, Sato R, et al. Changes in circulating adiponectin and metabolic hormone concentrations during parturipartum and lactation periods in Holstein dairy cows: adiponectin secretion changes in dairy cows. Anim Sci J. (2012) 83:788–95. doi: 10.1111/j.1740-0929.2012.01029.x

16. Singh SP, Haussler S, Gross JJ, Schwarz FJ, Bruckmaier RM, Sauerwein H. Effects of peripartum propylene glycol supplementation on nitrogen metabolism, body composition, and gene expression for the major protein degradation pathways in skeletal muscle in dairy cows. J Dairy Sci. (2008) 91:3512–27. doi: 10.3168/jds.2007-0920

17. Wuensch T, Wisnjet T, Janet T, Spitz W, Bosma M, Becker O, et al. Expression analysis of fibronectin type III domain-containing (FNDC) genes in inflammatory bowel disease and colorectal cancer. Gastroenterol Res Pract. (2019) 2019:1–11. doi: 10.1155/2019/3784172

18. Flori L, Testi L, Caldorene V. The "irisin system": From biological roles to pharmacological and nutraceutical perspectives. Life Sci. (2021) 267:118954. doi: 10.1016/j.lfs.2021.118954

19. Waseem R, Shamsi A, Mohammad T, Hassan MD, Kazim SN, Chaudhary AA, et al. FNDC5/Irisin: physiology and pathophysiology. Molecules. (2022) 27:1118. doi: 10.3390/molecules27031118

20. Zhang X, Hu C, Yuan YP, Ma ZG, Tang QZ. A brief overview about the physiology of fibronectin type III domain-containing 3. Cell Signal. (2020) 76:109685. doi: 10.1016/j.cellsig.2020.109685

21. Daudon M, Bigot Y, Dupont J, Price CA. Irisin and the fibronectin type III domain-containing family: structure, signaling and role in female reproduction. Reproduction. (2022) 164:R1–9. doi: 10.1530/REP-22-0037

22. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-a-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. (2012) 481:460–8. doi: 10.1038/nature10777

23. Ma EB, Sahar NE, Jeong M, Huh JY. Irisin exerts inhibitory effect on adipogenesis through regulation of Wnt signaling. Front Physiol. (2019) 10:1085. doi: 10.3389/fphys.2019.01085

24. Zhang Y, Li R, Meng Y, Li S, Donelan W, Zhao Y, et al. Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling. Diabetes. (2014) 63:514–25. doi: 10.2337/db13-1106

25. Brenmoehl J, Albrecht E, Komolka K, Schering L, Langhammer M, Hoellisch A, et al. Irisin is elevated in skeletal muscle and serum of mice immediately after acute exercise. Int J Biol Sci. (2014) 10:338–49. doi: 10.7150/ijbs.7972

26. Kim H, Warran CD, Jedrychowski M, Vidoni S, Kitase Y, Nagano K, et al. Irisin mediates effects on bone and fat via integrin receptors. Cell. (2018) 175:1576–68.e17. doi: 10.1016/j.cell.2018.10.025

27. Schumacher MA, Chinnam N, Ohashi T, Shah RS, Erickson JP. The structure of irisin reveals a novel intersubunit β-sheet fibronectin type III (FNIII) dimer. J Biol Chem. (2013) 288:3738–44. doi: 10.1074/jbc.M113.516641

28. Tominaoka K, Kondo C, Johmura Y, Nishizuka M, Imagawa M. The novel gene fad10, containing a fibronectin type III domain, has a significant role in adipogenesis. FEBS Lett. (2004) 577:49–54. doi: 10.1016/j.febslet.2004.09.062

29. Obhode KL, Akoypaon A, Waymire KG, MacGregor GR. FNDC3A is required for adherence between spermatozoa and sertoli cells. Dev Biol. (2006) 298:498–513. doi: 10.1016/j.ydbio.2006.06.054
40. Frühbeck G, Fernández-Quintana B, Paniagua M, Hernández-Pardos AW, Valentí V, Moncada R, et al. FNDCS, a novel adipokine that reduces lipogenesis and promotes fat browning in human visceral adipocytes. *Metabolism*. (2020) 108:154261. doi: 10.1016/j.metabol.2020.154261

41. Georgiadis A, Ma X, Bosma M, Graham E, Shilkova O, Maittissen F, et al. Fndc4, a highly identical ortholog of Irisin binds and activates a novel orphan receptor G-protein coupled receptor. *Diabetes/Steifwechs*. (2016) 11(5):01:s-0036-1588814. doi: 10.5555/s-0036-1588814

42. Mollouk N, Rame C, Naquin D, Iaszczyzyn Y, Touzet JL, Briant E, et al. Impact of the severity of negative energy balance on gene expression in the subcutaneous adipose tissue of periparturient primiparous Holstein dairy cows. *Identification of potential novel metabolic signals for the reproductive system.* *PloS ONE*. (2019) 14:e0222954. doi: 10.1371/journal.pone.0222954

43. Vandesempele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biol.* (2002) 3:research0034.1. doi: 10.1186/gb-2002-3-7-research0034

44. Albrecht E, Schering L, Buck F, Vlach K, Schober HC, Drevon CA, et al. Irisin: Still chasing shadows. *Mol Metab.* (2020) 34:124–35. doi: 10.1007/s40893-020-00106-3

45. Lecker SH, Zakin A, Cao P, Arena R, Allsup K, Daniels KM, et al. Expression of the irisin precursor FNDCS in skeletal muscle correlates with aerobic exercise performance in patients with heart failure. *Circ Heart Fail*. (2012) 5:812–8. doi: 10.1161/CIRCHEARTFAILURE.111.969543

46. Huh JY, Panagiotou G, Mougiou V, Brinkkemter M, Vamvios MT, Schneider BE, et al. FNDCS and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II mRNA expression and circulating concentrations in response to weight loss and exercise. *Metabolism*. (2012) 61:1725–38. doi: 10.1016/j.metabol.2012.09.002

47. Moreno-Navarrete JM, Ortega F, Serrano M, Guerra E, Pardo G, Tihanones F, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. *J Clin Endocrinol Metab*. (2013) 98:E769–78. doi: 10.1210/jc.2012-2749

48. Roca-Rivada A, Castelao C, Senin LL, Landrove MO, Baltar J, Crujeiras AB, et al. FNDCS/irisin is not only a myokine but also an adipokine. *PloS ONE*. (2013) 8:e60563. doi: 10.1371/journal.pone.0060563

49. Kuridova T, Balaz M, Vician M, Maderova D, Vlcek M, Valkovic L, et al. Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: *in vivo* and *in vitro* studies: human Fndc5/irisin in prediabetes, type 2 diabetes and exercise. *J Physiol*. (2015) 592:1091–107. doi: 10.1113/jphysiol.2013.264655

50. Xiong Y, Wu Z, Zhang B, Wang C, Mao F, Liu X, et al. Fndc5 loss-of-function attenuates exercise-induced browning of white adipose tissue in mice. *FASEB J*. (2019) 33:5876–86. doi: 10.1096/fj.201801754RR

51. Komolka R, Albrecht E, Schering L, Brennhoel J, Hoeflich A, Maak S. Locus characterization and gene expression of bovine FNDCS5: is the myokine irisin relevant in cattle? *PLoS ONE*. (2014) 9:e89066. doi: 10.1371/journal.pone.0089060

52. Al-Dagheri NM, Alkhafry KM, Rahman S, Amer OE, Vinodson B, Sabico S, et al. Irisin as a predictor of glucose metabolism in children: sexually dimorphic effects. *Eur J Clin Invest.* (2014) 44:1119–24. doi: 10.1111/eci.12196

53. Anastasialakis AD, Polyzos SA, Saridakis ZG, Kyngopoulos G, Skouvaklidou EC, Molyvass D, et al. Circulating irisin in healthy, young individuals: day-night rhythm, effects of food intake and exercise, and associations with gender, physical activity, diet, and body composition. *J Clin Endocrinol Metab*. (2019) 99:3247–55. doi: 10.1210/jc.2014-1367

54. Tian Q, Stepanants SB, Mao M, Weng L, Feetham MC, Doyle MJ, et al. Integrated genomic and proteomic analyses of gene expression in mammalian cells. *Mol Cell Proteomics*. (2004) 3:960–9. doi: 10.1074/mcp.M400055-MCP200

55. Cox B, Kislenger T, Emili A. Integrating gene and protein expression data: pattern analysis and profile mining. *Methods*. (2003) 35:303–14. doi: 10.1016/S1046-2024(03)00081-2

56. Fatouros IG. Is irisin the new player in exercise-induced adaptations or not? A 2017 update. *Clin Chem Lab Med*. (2018) 56:525–48. doi: 10.1515/cclm-2017-0074

57. Arias-Losie M, Ranchal J, Romero-Gómez M, Crespo J, Irisin, a link among fatty liver disease, physical inactivity and insulin resistance. *IJMS*. (2014) 15:23163–78. doi: 10.3390/ijms151223163

58. de Oliveira M, Mathias LS, Rodrigues BM, Mariani BG, Graceli JB, de Sibio MT, et al. The roles of triiodothyronine and irisin in improving the lipid profile and directing the browning of human adipose subcutaneous cells. *Mol Cell Endocrinol*. (2020) 506:110744. doi: 10.1016/j.mce.2020.110744

59. Gao S, Li F, Li H, Huang Y, Liu Y, Chen Y. Effects and molecular mechanism of GSTR-irisin on lipolysis and autocrine function in 3T3-L1 adipocytes. *PLoS ONE*. (2016) 11:e0147480. doi: 10.1371/journal.pone.0147480

60. Xiong QX, Chen D, Sun HJ, Ding L, Wang JJ, Chen Q, et al. FNDCS overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity. *Biotechnol Bioproc Acta*. (2015) 185:1867–75. doi: 10.1007/s00641-015-9918-2

61. Huh JY, Dincer F, Mesfum F, Mantzoros CS. Irisin stimulates muscle growth-related genes and regulates adipocyte differentiation and metabolism in humans. *Int J Obes*. (2018) 38:1538–44. doi: 10.1038/s41446-018-0211-z

62. Wang C, Wang L, Li W, Yan F, Tian M, Wu C, et al. Irisin has no effect on lipolysis in 3T3-L1 adipocytes or fatty acid metabolism in HepG2 hepatocytes. *Endocrino*. (2015) 198:90–9. doi: 10.1007/s12020-014-0458-9

63. Georgiadis A, Lopez-Salazar V, Merahl RE, Karikari RA, Ma X, Mourão A, et al. Orphan GPR116 mediates the insulin sensitizing effects of the hepatokine FNDC4 in adipose tissue. *Nat Commun*. (2021) 12:2999. doi: 10.1038/s41467-021-22579-1